Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
doi 10.4137/cmt.s2314
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis

Journal of Hepatology
Hepatology
2019English

TARBP2-mediated Destabilization of Nanog Overcomes Sorafenib Resistance in Hepatocellular Carcinoma

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

The Microenvironmental and Metabolic Aspects of Sorafenib Resistance in Hepatocellular Carcinoma

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

A Clinical Phase II Study of Sorafenib in Advanced Hepatocellular Carcinoma

Anaplastology
2012English

Attenuation of Liver Stiffness in Sorafenib-Treated Patients With Advanced Hepatocellular Carcinoma

Hepatoma Research
2017English

Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity

Internal Medicine
Internal MedicineMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy